Many presume that vaccines produced by the Serum Institute of India (SII) are “Indian vaccines” by default. Covishield, the mainstay of India’s vaccination programme used in more than 85% of India’s inoculations, is the result of a mutually beneficial international collaboration. At least half of the doses SII produces are paid for by other countries and global platforms, but manufactured in India. The deadly second wave created an unforeseen emergency and disrupted India’s role as a global supplier of vaccines. A recent analysis of company filings by the top four global vaccine manufacturers found that 90% all the vaccines produced in 2021 Q1 in the United States (US) and Europe were administered on populations within North America and Europe. Even in Q2, the situation is going to be the same. This brings to the front the importance of creating and expanding vaccine production capacity in the developing world.